Hypoglycemia

There are 645 papers on hypoglycemia in aging research: 156 trials and 175 observational studies in people, 40 in animals, 255 reviews.

Disease

645 papers study it171 more mention it236 findings

MeSH

55 new papers in 30 daysSee all 816 papers on hypoglycemia

“Semaglutide increased the risk of hypoglycemia compared to placebo”
Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysisScientific reports2025doi:10.1038/s41598-025-09807-0
  • Human trial156
  • Humans175
  • Animals38
  • Model organisms2
  • In silico7

Interventions

42

Tirzepatide

no changein humans8downin humans6RR 0.46

14 studies
  1. Tirzepatide showed no clear effect on hypoglycemia in humans during Ramadan fasting (none reported).

    Human trialduring Ramadan fasting2.5 mg weeklyn = 109

  2. Tirzepatide decreases hypoglycemia in humans (compared with insulin glargine).

    Human trialcompared with insulin glargine5, 10, or 15 mg104 weeksn = 1,500

  3. Tirzepatide showed no clear effect on hypoglycemia in humans.

    Human trialolder adults without obesity (BMI < 30 kg/m2); regardless of concurrent insulin or sulfonylurea use

  4. Tirzepatide decreases hypoglycemia in humans (added to insulin glargine, compared with insulin lispro added to insulin glargine) (0.4 vs 4.4 events per patient-year).

    Human trialadded to insulin glargine, compared with insulin lispro added to insulin glargine

  5. Tirzepatide showed no clear effect on hypoglycemia in participants achieving HbA1c <5.7%.

    Human trialin participants achieving HbA1c <5.7%40 weeks

  6. Tirzepatide showed no clear effect on hypoglycemia in humans (baseline HbA1c >8.5% versus ≤8.5%).

    Human trialbaseline HbA1c >8.5% versus ≤8.5%5, 10 or 15 mg52 weeks

  7. Tirzepatide decreases hypoglycemia in humans (versus insulin).

    Human trialversus insulin15 mg

  8. Tirzepatide decreases hypoglycemia in humans (versus insulin glargine) (6-9% vs 19% with glargine).

    Human trialversus insulin glargine52 weeks

  9. Tirzepatide showed no clear effect on hypoglycemia in humans (monotherapy in type 2 diabetes).

    Human trialmonotherapy in type 2 diabetesonce-weekly5, 10, or 15 mg40 weeksn = 478

  10. Tirzepatide was not clearly linked with hypoglycemia in humans (severe hypoglycaemia in type 1 diabetes and obesity).

    Humanssevere hypoglycaemia in type 1 diabetes and obesity5 mg weekly12 months

All 14

More on Tirzepatide

GLP-1 receptor agonists

no changein humans6downin humans2HR 1.1

8 studies
  1. GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans (add-on to metformin in type 2 diabetes).

    Human trialadd-on to metformin in type 2 diabetes

  2. GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans.

    Human trialas part of glucose-dependent strategy (with nonsulfonylurea OAM) vs sulfonylurea and insulin glargine24 weeksn = 26

  3. GLP-1 receptor agonists decrease hypoglycemia in humans (compared with sulfonylurea and insulin glargine strategy) (total 10.2% vs 53.8%; P < .001).

    Human trialcompared with sulfonylurea and insulin glargine strategy

  4. GLP-1 receptor agonists were not clearly linked with hypoglycemia in humans (Type 2 diabetes and CKD stages 2–4; compared with DPP-4 inhibitors).

    HumansType 2 diabetes and CKD stages 2–4; compared with DPP-4 inhibitors

  5. GLP-1 receptor agonists were not clearly linked with hypoglycemia in humans (propensity-matched comparison with non-GLP-1 users) (HR 1.10 (95% CI 0.60-1.76)).

    Humanspropensity-matched comparison with non-GLP-1 users12 monthsn = 1,391

  6. GLP-1 receptor agonists decrease hypoglycemia in humans.

    Review

  7. GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans.

    Review

  8. GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans (added to basal insulin, compared with rigorously titrated basal insulin alone) (RR 1.01, 95% CI 0.86 to 1.18).

    Reviewadded to basal insulin, compared with rigorously titrated basal insulin alone

More on GLP-1 receptor agonists

Acarbose

no changein humans4downin humans2upin humans1

7 studies
  1. Acarbose decreases hypoglycemia in humans (2 vs 13 patients).

    Human trial6 months

  2. Acarbose decreases hypoglycemia in H-MAGE patients on twice-daily premixed insulin aspart 30 (2% vs. 24%, χ(2) = 9.61, P < 0.01).

    Human trialin H-MAGE patients on twice-daily premixed insulin aspart 302 weeksn = 86

  3. Acarbose showed no clear effect on hypoglycemia in humans.

    Human trial3 yearsn = 1,946

  4. Acarbose showed no clear effect on hypoglycemia in humans (added to insulin).

    Human trialadded to insulin24 weeks

  5. Acarbose showed no clear effect on hypoglycemia in humans (added to diet and insulin therapy).

    Human trialadded to diet and insulin therapy36 weeks

  6. Acarbose induces hypoglycemia in humans (non-insulin-dependent diabetic patients) (12 patients).

    Human trialnon-insulin-dependent diabetic patientsn = 90

  7. Acarbose showed no clear effect on hypoglycemia in humans.

    Review

More on Acarbose

Linagliptin

no changein humans5OR 1.12

5 studies
  1. Linagliptin showed no clear effect on hypoglycemia in humans.

    Human trial

  2. Linagliptin showed no clear effect on hypoglycemia in humans (compared with placebo).

    Human trialcompared with placebo5 mg qd24 weeks

  3. Linagliptin showed no clear effect on hypoglycemia in humans (all-patient population, 24 weeks, versus placebo) (HR 1.07; 95% CI 0.84–1.36; P = 0.5943).

    Human trialall-patient population, 24 weeks, versus placebo5 mg24 weeksn = 1,489

  4. Linagliptin showed no clear effect on hypoglycemia in humans (patients not taking sulfonylureas) (1.2% linagliptin vs 1.1% placebo).

    Human trialpatients not taking sulfonylureas5 mg/d24 weeks

  5. Linagliptin showed no clear effect on hypoglycemia in humans (type 2 diabetes mellitus) (OR 1.12, 95% CI: 0.85, 1.48).

    Reviewtype 2 diabetes mellitus24 weeks

More on Linagliptin

Semaglutide

downin humans1upin humans1no changein humans1

3 studies
  1. Semaglutide induces hypoglycemia in an occult insulinoma patient (35 mg/dL).

    Human trialin an occult insulinoma patientfemalesn = 1

  2. Semaglutide showed no clear effect on hypoglycemia in humans (non-elderly and elderly patients with type 2 diabetes).

    Human trialnon-elderly and elderly patients with type 2 diabetesonce-weekly subcutaneous0.5 and 1.0 mg

  3. Semaglutide is linked with lower hypoglycemia in one patient with recurrent hypoglycemia and poorly controlled diabetes.

    Humansin one patient with recurrent hypoglycemia and poorly controlled diabetesmalesn = 1

More on Semaglutide

SGLT2 inhibitors

no changein humans3

3 studies
  1. SGLT2 inhibitors showed no clear effect on hypoglycemia in patients with HFrEF without diabetes.

    Human trialin patients with HFrEF without diabetesthree monthsn = 130

  2. SGLT2 inhibitors were not clearly linked with hypoglycemia in humans (versus new DPP4i, 30-day risk).

    Humansversus new DPP4i, 30-day risk30 days

  3. SGLT2 inhibitors showed no clear effect on hypoglycemia in hypertensive patients with diabetes.

    Reviewin hypertensive patients with diabetes

More on SGLT2 inhibitors

Empagliflozin

no changein humans2

2 studies
  1. Empagliflozin showed no clear effect on hypoglycemia in individuals with HNF1A-MODY as add-on treatment.

    Human trialin individuals with HNF1A-MODY as add-on treatment25 mg4 weeksn = 18

    Drug lowered blood sugar in an inherited form of diabetes

    Diabetes care
  2. Empagliflozin showed no clear effect on hypoglycemia in humans (adjunctive to automated insulin delivery).

    Reviewadjunctive to automated insulin delivery

More on Empagliflozin

Dapagliflozin

upin humans2

2 studies
  1. Dapagliflozin increases hypoglycemia in older patients, by age stratum (20.2 vs 17.7% (≥65 years)).

    Human trialin older patients, by age stratum10 mgup to 104 weeks

  2. Dapagliflozin is linked with hypoglycemia in humans.

    Humansin a nondiabetic patient with end-stage familial hypertrophic cardiomyopathy and MYH7 mutationsfemales

More on Dapagliflozin

GLP-1 receptor agonists + SGLT2 inhibitors

no changein humans2HR 0.799

2 studies
  1. GLP-1 receptor agonists + SGLT2 inhibitors showed no clear effect on hypoglycemia in humans (compared with monotherapy).

    Human trialcompared with monotherapy

  2. GLP-1 receptor agonists + SGLT2 inhibitors showed no clear effect on hypoglycemia in humans (versus SGLT2 inhibitors alone) (1.3% vs 1.7%; HR 0.799).

    Reviewversus SGLT2 inhibitors alone365 days after treatment initiationn = 1,118

More on GLP-1 receptor agonists + SGLT2 inhibitors

Sulfonylureas

upin humans2

2 studies
  1. Sulfonylureas induce hypoglycemia in patients with compensated cirrhosis.

    Reviewin patients with compensated cirrhosis

  2. Sulfonylureas induce hypoglycemia in humans.

    Review

More on Sulfonylureas

Liraglutide

no changein humans2

2 studies
  1. Liraglutide showed no clear effect on hypoglycemia in humans.

    Human trial1.2 mg3 weeksfemalesn = 11

  2. Liraglutide showed no clear effect on hypoglycemia in humans (added to insulin therapy).

    Human trialadded to insulin therapy6 monthsn = 20

More on Liraglutide

Diet

no changein humans1

1 study
  1. Diet showed no clear effect on hypoglycemia in humans (1.4 percentage points (95% CI -1.0, 3.7)).

    Human trialthree monthsn = 28

  2. Diet showed no clear effect on hypoglycemia in humans (type 1 diabetes with overweight or obesity) (P > .05).

    Human trialtype 1 diabetes with overweight or obesity3 monthsn = 28

More on Diet

Metformin + dapagliflozin + saxagliptin

downin humans1

1 study
  1. Metformin + dapagliflozin + saxagliptin decreases hypoglycemia in humans (Newly diagnosed type 2 diabetes; compared with stepwise add-on therapy).

    Human trialNewly diagnosed type 2 diabetes; compared with stepwise add-on therapy104 weeks

More on Metformin + dapagliflozin + saxagliptin

Sitagliptin + empagliflozin

no changein humans1

1 study
  1. Sitagliptin + empagliflozin showed no clear effect on hypoglycemia in humans (add-on to metformin and sitagliptin, versus placebo).

    Human trialadd-on to metformin and sitagliptin, versus placebofixed-dose combination24 weeksn = 230

More on Sitagliptin + empagliflozin

HRS-7535

upin humans1

1 study
  1. HRS-7535 induces hypoglycemia in humans (treatment-emergent, documented hypoglycemia) (5.8% (9 pts); no Level 2 or higher events).

    Human trialtreatment-emergent, documented hypoglycemiaoral small molecule15–90 mg16 weeks

More on HRS-7535

All 42

Effects

8

Cognitive function

downin humans2

2 studies
  1. Hypoglycemia impairs cognitive function in seniors.

    Reviewin seniors

  2. Hypoglycemia impairs cognitive function in older diabetic patients (SMD 0.58, 95% CI 0.88-0.28).

    Reviewin older diabetic patients

Hospital readmissions

upin humans1

1 study
  1. Hypoglycemia is linked with higher hospital readmissions in humans (hospitalized older adults, 1:2 propensity score matched) (IRR=2.019, 95 % CI: 1.970-2.069).

    Humanshospitalized older adults, 1:2 propensity score matched

Cardiac injury

upin reviews1

1 study
  1. Hypoglycemia increases cardiac injury (recurrent hypoglycemia).

    Reviewrecurrent hypoglycemiaheartchronic

Electrophysiological disturbances

upin reviews1

1 study
  1. Hypoglycemia induces electrophysiological disturbances.

    Reviewheartacute

nNOS gene expression

upin rats1

1 study
  1. Hypoglycemia increases nNOS gene expression in rats.

    AnimalsVMNdm Ghrh neuron

More on nNOS gene expression

Cardiovascular consequences

upin reviews1

1 study
  1. Hypoglycemia increases cardiovascular consequences in older adults submitted to tight glycemic control.

    Reviewin older adults submitted to tight glycemic control

Cognitive dysfunction

no changein humans1

1 study
  1. Hypoglycemia was not clearly linked with cognitive dysfunction in humans (P=0.1106).

    HumansKorean patients with type 2 diabetes mellitus; hypoglycemic events versus no hypoglycemic eventsMean follow-up of 3.4±0.9 yearsn = 1,957

More on Cognitive dysfunction

Counter-regulatory responses to hypoglycemia

downin humans1

1 study
  1. Hypoglycemia impairs counter-regulatory responses to hypoglycemia in humans (frequent hypoglycemic episodes in diabetic patients).

    Reviewfrequent hypoglycemic episodes in diabetic patients

Upstream

7

Older age

no changein humans1

1 study
  1. Older age was not clearly linked with hypoglycemia in humans (hospitalized in non-acute settings).

    Humanshospitalized in non-acute settings

AstC-R2

downin flies1

1 study
  1. AstC-R2 protects against hypoglycemia in flies during fasting.

    Model organismsduring fastingadipokinetic-hormone-producing cells

More on AstC-R2

HbA1c

no changein humans1OR 0.95

1 study
  1. HbA1c was not clearly linked with hypoglycemia in humans (dementia and T2DM) (OR = 0.95, p = 0.140).

    Humansdementia and T2DMtwo-yearn = 3,877

More on HbA1c

Lactate

downin mice1

1 study
  1. Lactate prevents hypoglycemia in mice after calorie restriction and 23-hour fast.

    Animalsafter calorie restriction and 23-hour fast

More on Lactate

GHR

downin mice1

1 study
  1. GHR prevents hypoglycemia in mice (shown by liver-specific knockout after calorie restriction and 23-hour fast).

    Animalsshown by liver-specific knockout after calorie restriction and 23-hour fastliver

More on GHR

Age

no changein humans1

1 study
  1. Age showed no clear effect on hypoglycemia in humans (age <65 vs ≥65 years, with insulin glargine).

    Human trialage <65 vs ≥65 years, with insulin glargine

Ghrelin

downin mice1

1 study
  1. Ghrelin protects against hypoglycemia in beta1AR-deficient mice under severe caloric restriction.

    Animalsin beta1AR-deficient mice under severe caloric restriction

More on Ghrelin

Associations

75

GLP-1 receptor agonists

upin humans7downin humans3downin reviews1RR 1.263

11 studies
  1. GLP-1 receptor agonists raise the risk of hypoglycemia in humans (older vs younger adults) (LOR 0.97, p < 0.001).

    Human trialolder vs younger adults

  2. GLP-1 receptor agonists raise the risk of hypoglycemia in humans (adjunctive to insulin in type 1 diabetes with overweight or obesity) (OR 1.32 (95% CI 1.01 to 1.72)).

    Human trialadjunctive to insulin in type 1 diabetes with overweight or obesity

  3. GLP-1 receptor agonists are linked with a higher risk of hypoglycemia in humans (obesity and heart failure) (RR 1.263, 95% CI 1.169-1.364).

    Humansobesity and heart failure5 years

    Drugs linked to falls in older adults with obesity and heart failure

    AHA Scientific Sessions 2026 abstract
  4. GLP-1 receptor agonists are linked with a higher risk of hypoglycemia in adults surviving dialysis-requiring acute kidney injury (OR 5.4 (95% CI 4.87-5.99)).

    Humansin adults surviving dialysis-requiring acute kidney injury

  5. GLP-1 receptor agonists are linked with a higher risk of hypoglycemia in humans (when combined with anabolic-androgenic steroids).

    Humanswhen combined with anabolic-androgenic steroids

  6. GLP-1 receptor agonists are linked with a lower risk of hypoglycemia in humans (versus sulfonylureas) (HR 0.21 (95% CI 0.16-0.27)).

    Humansversus sulfonylureas

  7. GLP-1 receptor agonists are associated with hypoglycemia in humans after spine surgery; perioperative exposure.

    Reviewafter spine surgery; perioperative exposure

  8. GLP-1 receptor agonists raise the risk of hypoglycemia in type 1 diabetes phase 3 trials.

    Reviewin type 1 diabetes phase 3 trialsdaily injectable

  9. GLP-1 receptor agonists lower the risk of hypoglycemia in humans (type 2 diabetes).

    Reviewtype 2 diabetes

  10. GLP-1 receptor agonists lower the risk of hypoglycemia in humans (type 2 diabetes).

    Reviewtype 2 diabetes

All 11

More on GLP-1 receptor agonists

Insulin

upin humans7upin silico1OR 4.22–4.64

8 studies
  1. Insulin is associated with hypoglycemia in humans (average 0.13% per month).

    Humans

  2. Insulin is linked with a higher risk of hypoglycemia in humans (hospitalized patients with type 2 diabetes) (OR 4.22, 95% CI 2.14-6.28).

    Humanshospitalized patients with type 2 diabetes

  3. Insulin is linked with a higher risk of hypoglycemia in humans (dementia and T2DM) (OR = 4.64, p < 0.001).

    Humansdementia and T2DMtwo-yearn = 3,877

  4. Insulin is linked with a higher risk of hypoglycemia in humans (patients aged over 65 on insulin versus sulfonylureas) (34% vs 5% with more than one documented episode (sulphonylurea); 2% metformin-only; p<0.001).

    Humanspatients aged over 65 on insulin versus sulfonylureasn = 79

  5. Insulin is linked with a higher risk of hypoglycemia in patients with type 2 diabetes.

    Humansin patients with type 2 diabetes

  6. Insulin raises the risk of hypoglycemia in elderly individuals with type 2 diabetes.

    Reviewin elderly individuals with type 2 diabetes

  7. Insulin raises the risk of hypoglycemia in humans.

    Review

  8. Insulin raises the risk of hypoglycemia in silico (modeled drug-induced hypoglycemia) (8.64 events per person-year (65-79 years); 12.06 events per person-year (80 years and older)).

    In silicomodeled drug-induced hypoglycemiabasal

More on Insulin

SGLT2 inhibitors

downin humans6upin humans1RR 0.27–0.53

7 studies
  1. SGLT2 inhibitors are linked with a higher risk of hypoglycemia in adults with type 2 diabetes mellitus undergoing open surgical tracheostomy (OR 2.01, 95% CI 1.30-3.13).

    Humansin adults with type 2 diabetes mellitus undergoing open surgical tracheostomy180 days

  2. SGLT2 inhibitors are linked with a lower risk of hypoglycemia in humans (versus sulfonylureas) (HR 0.21 (95% CI 0.13-0.33)).

    Humansversus sulfonylureas

  3. SGLT2 inhibitors are linked with a lower risk of hypoglycemia in humans (versus dpp-4 inhibitor users) (HR 0.61; RD -1.6 per 1000 person-years).

    Humansversus dpp-4 inhibitor usersn = 29,916

  4. SGLT2 inhibitors are linked with a lower risk of hypoglycemia in humans (new users compared with sulfonylurea initiation, after propensity score decile adjustment).

    Humansnew users compared with sulfonylurea initiation, after propensity score decile adjustment

  5. SGLT2 inhibitors lower the risk of hypoglycemia in humans (fasting during Ramadan) (RR 0.53, 95% CI 0.29-0.97).

    Reviewfasting during Ramadan

  6. SGLT2 inhibitors lower the risk of hypoglycemia in humans (RR 0.27, 95% CI 0.09–0.84).

    ReviewWith metformin in type 2 diabetes mellitus, compared with other metformin-containing oral dual therapies52 weeks

  7. SGLT2 inhibitors lower the risk of hypoglycemia in humans (type 2 diabetes).

    Reviewtype 2 diabetes

More on SGLT2 inhibitors

Tirzepatide

upin humans4downin humans3RR 0.46–3.83

7 studies
  1. Tirzepatide lowers the risk of hypoglycemia in humans (add-on to oral anti-hyperglycemic drugs, versus once-daily basal insulin).

    Human trialadd-on to oral anti-hyperglycemic drugs, versus once-daily basal insulin

  2. Tirzepatide is associated with hypoglycemia in humans (most hypoglycemic subjects were insulin users).

    Humansmost hypoglycemic subjects were insulin users6 monthsn = 55

  3. Tirzepatide is associated with hypoglycemia in humans (115 cases).

    Humans

  4. Tirzepatide is associated with hypoglycemia in humans after switch from GLP-1 RA with concurrent insulin therapy (8 patients (12.1%)).

    Humansafter switch from GLP-1 RA with concurrent insulin therapy6 monthsn = 66

  5. Tirzepatide lowers the risk of hypoglycemia in humans (compared with daily insulin glargine and degludec) (RR 0.46, 95% CI (0.28, 0.75)).

    Reviewcompared with daily insulin glargine and degludeconce-weekly

  6. Tirzepatide lowers the risk of hypoglycemia in humans (versus iDegLira) (vs iDegLira OR 0.35, 95% CI 0.16–0.79).

    Reviewversus iDegLira15 mg

  7. Tirzepatide raises the risk of hypoglycemia in humans (pooled across nine RCTs) (pooled RR=3.83, 95% CI 1.19–12.30, P=0.02).

    Reviewpooled across nine RCTs15 mg

More on Tirzepatide

DPP-4 inhibitors

downin humans4upin humans2RR 1.08

6 studies
  1. DPP-4 inhibitors are linked with a lower risk of hypoglycemia in residents of LTCFs with diabetes receiving metformin compared with long-acting insulin (sHR 0.36 (95% CI, 0.23-0.56)).

    Humansin residents of LTCFs with diabetes receiving metformin compared with long-acting insulin5-year follow-upn = 4,414

  2. DPP-4 inhibitors are linked with a lower risk of hypoglycemia in humans (nursing home residents) (HR = 0.57, 95% CI 0.34-0.94).

    Humansnursing home residents1 yearn = 2,016

  3. DPP-4 inhibitors lower the risk of hypoglycemia in older adults with type 2 diabetes.

    Reviewin older adults with type 2 diabetes

  4. DPP-4 inhibitors lower the risk of hypoglycemia in humans (type 2 diabetes).

    Reviewtype 2 diabetes

  5. DPP-4 inhibitors raise the risk of hypoglycemia in addition to standard care in older patients with type 2 diabetes (RR 1.08, 95% CI 1.01-1.16).

    Reviewin addition to standard care in older patients with type 2 diabetesn = 19,317

  6. DPP-4 inhibitors raise the risk of hypoglycemia in addition to standard care (RR 1.08; 95%CI 1.01-1.16).

    Reviewin addition to standard care

More on DPP-4 inhibitors

Frailty

upin humans5

5 studies
  1. Hypoglycemia is associated with frailty in humans.

    Humanselderly inpatients with diabetes; indirect association through malnutrition or risk of malnutritionn = 427

  2. Frailty is linked with a higher risk of hypoglycemia in humans (type 2 diabetes).

    Humanstype 2 diabetes

  3. Frailty is associated with hypoglycemia in humans (diabetes).

    Reviewdiabetes

  4. Hypoglycemia raises the risk of frailty in older people with diabetes.

    Reviewin older people with diabetes

  5. Frailty raises the risk of hypoglycemia in humans (diabetes).

    Reviewdiabetes

Sulfonylureas

upin humans3upin silico1upin reviews1+45%

5 studies
  1. Sulfonylureas are associated with hypoglycemia in humans (type 2 diabetes mellitus on sulfonylureas) (45%).

    Humanstype 2 diabetes mellitus on sulfonylureasn = 40

  2. Sulfonylureas are linked with a higher risk of hypoglycemia in patients with type 2 diabetes.

    Humansin patients with type 2 diabetes

  3. Sulfonylureas raise the risk of hypoglycemia.

    Review

  4. Sulfonylureas raise the risk of hypoglycemia in humans.

    Review

  5. Sulfonylureas raise the risk of hypoglycemia in silico (modeled drug-induced hypoglycemia) (4.32 events per person-year (65-79 years); 6.03 events per person-year (80 years and older)).

    In silicomodeled drug-induced hypoglycemia

More on Sulfonylureas

Liraglutide

downin humans3upin humans1HR 0.891

4 studies
  1. Liraglutide lowers the risk of hypoglycemia in humans (compared with traditional antidiabetic drugs).

    Human trialcompared with traditional antidiabetic drugs

  2. Liraglutide lowers the risk of hypoglycemia in humans (0.03–0.14 vs 1.23 events/year).

    Human trial26 weeksn = 1,091

  3. Liraglutide is linked with a lower risk of hypoglycemia in humans (versus dulaglutide, propensity-matched cohort) (HR 0.891 (95% CI 0.808-0.983)).

    Humansversus dulaglutide, propensity-matched cohort1 yearn = 36,851

  4. Liraglutide raises the risk of hypoglycemia in humans (adjunct use in T1DM; dose-dependent).

    Reviewadjunct use in T1DM; dose-dependent

More on Liraglutide

Dementia

upin humans3HR 2.689

3 studies
  1. Hypoglycemia is associated with dementia in humans (Korean patients with type 2 diabetes mellitus; multiple-adjusted analysis) (HR 2.689, 95% CI 1.080–6.694; P=0.0335).

    HumansKorean patients with type 2 diabetes mellitus; multiple-adjusted analysisMean follow-up of 3.4±0.9 yearsn = 1,957

  2. Hypoglycemia raises the risk of dementia in the elderly.

    Reviewin the elderly

  3. Hypoglycemia raises the risk of dementia in humans.

    Review

More on Dementia

Cognitive impairment

upin humans3

3 studies
  1. Hypoglycemia is associated with cognitive impairment in humans.

    Humanshistory of hypoglycemia in inpatients with diabetes mellitus; multivariable logistic regressionn = 87

  2. Hypoglycemia is associated with cognitive impairment in humans (diabetes mellitus) (AOR 2.87, 95% CI 1.62–5.06).

    Humansdiabetes mellitusn = 415

  3. Hypoglycemia is linked with a higher risk of cognitive impairment in patients with T2DM.

    Humansin patients with T2DMn = 240

More on Cognitive impairment

Semaglutide

upin humans1mixedin humans1downin reviews1

3 studies
  1. Semaglutide raises the risk of hypoglycemia in humans (compared with placebo).

    Human trialcompared with placebo

  2. Semaglutide is associated with hypoglycemia in humans (add-on to SGLT2i and metformin) (hypoglycemic events fell to none in 3 patients and rose in 4 patients).

    Human trialadd-on to SGLT2i and metforminoraltwo weeksn = 10

  3. Semaglutide lowers the risk of hypoglycemia.

    Revieworal

More on Semaglutide

Insulin glargine + lixisenatide

downin humans2

2 studies
  1. Insulin glargine + lixisenatide lowers the risk of hypoglycemia in humans during Ramadan fasting.

    Human trialduring Ramadan fasting

  2. Insulin glargine + lixisenatide is linked with a lower risk of hypoglycemia in humans (type 2 diabetes, ethnic minorities) (2.5 vs 3.8 vs 7.5 per 100 person-years).

    Humanstype 2 diabetes, ethnic minoritiesup to 12 months

More on Insulin glargine + lixisenatide

Linagliptin

downin humans1upin humans1

2 studies
  1. Linagliptin raises the risk of hypoglycemia in humans (11.9% linagliptin vs 7.3% placebo).

    Human trialoverall incidence, attributed to more sulfonylurea use in the linagliptin group (26.8% vs 18.4%)5 mg/d24 weeksn = 1,421

  2. Linagliptin is linked with a lower risk of hypoglycemia in humans (hospitalized patients with type 2 diabetes).

    Humanshospitalized patients with type 2 diabetes

More on Linagliptin

Canagliflozin

upin humans2

2 studies
  1. Canagliflozin raises the risk of hypoglycemia in humans.

    Human trial

  2. Canagliflozin raises the risk of hypoglycemia in humans (on background blood glucose-lowering therapy) (modestly higher than placebo).

    Human trialon background blood glucose-lowering therapy100 mg and 300 mg26 weeks

More on Canagliflozin

Control diet low in plants

upin humans1

1 study
  1. Control diet low in plants raise the risk of hypoglycemia in humans (+0.81% (95% CI, 0.21-1.40) TBR).

    Human trial6 monthsn = 226

  2. Control diet low in plants raise the risk of hypoglycemia in humans (prediabetes and overweight/obesity) (0.81% [0.21-1.40], P = 0.024).

    Human trialprediabetes and overweight/obesity6 months

More on Control diet low in plants

All 75

Trial sponsors

Funding

6 grants since 2018

National Institute of Diabetes and Digestive and Kidney Diseases$2.9MNational Institute on Aging$714KUS Department of Veterans Affairs

Latest

Dec 2025: 12Jan 2026: 36Feb 2026: 42Mar 2026: 41Apr 2026: 7May 2026: 11Jun 2026: 31Jul 2026: 19Aug 2026: 24Sep 2026: 12Oct 2026: 33Nov 2026: 26294 papers in 12 months

See all 816 papers on hypoglycemia